Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 6/20 | 0.49 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.48 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.46 |
| ▸ | GPR39 | O43194 | 1/20 | 0.45 |
| ▸ | BRAF | P15056 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.43 |
| ▸ | HPGD | P15428 | 2/20 | 0.43 |
| ▸ | CD38 | P28907 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.42 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.42 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL960125 | 0.85 | PTGDR (0.57) | CNR1PTGDRGPR39NPSR1HPGD | |
| SCHEMBL958637 | 0.84 | BRAF (0.48) | CNR1BRAFLMNAPOLBGABRA2 | |
| SCHEMBL958112 | 0.80 | GPR52 (0.48) | CNR1PTGDRGPR39HPGDLMNA | |
| SCHEMBL4494699 | 0.78 | PTGDR (0.80) | PTGDR | |
| SCHEMBL1513185 | 0.77 | LMNA (0.44) | PTGDRMEN1LMNAPOLBKMT2A | |
| SCHEMBL1513180 | 0.76 | LMNA (0.43) | PTGDRLMNAGABRA2GABRB2 | |
| SCHEMBL961086 | 0.76 | TDP1 (0.51) | NPSR1HPGDLMNAPOLBGABRA2 | |
| SCHEMBL1513233 | 0.75 | GABRA2 (0.40) | PTGDRNPSR1HPGDLMNAGABRA2 | |
| SCHEMBL1513263 | 0.74 | LMNA (0.43) | PTGDRLMNAGABRA2GABRB2 | |
| SCHEMBL1553909 | 0.73 | PIK3CA (0.52) | CNR1BRAFLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110009421-A1 | COMPOUND HAVING 6-MEMBERED AROMATIC RING | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-01-13 | — | — | US | disclosed |
| EP-2253618-A1 | COMPOUND HAVING 6-MEMBERED AROMATIC RING | Takeda Pharmaceutical Company Limited (JP) | 2010-11-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110009421-A1 | COMPOUND HAVING 6-MEMBERED AROMATIC RING | GPR4, NR3C2, NR5A2 | CNR1 63/4885PTGDR 528/4885SLC2A1 1702/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.